FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
Duke ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, Shen YL, Isikwei E, Zhao H, Bi Y, Liu J, Rahman NA, Wearne E, Leighton JK, Stephenson M, Ojofeitimi I, Scepura B, Nair A, Pazdur R, Beaver JA, Singh H.
Duke ES, et al. Among authors: chatterjee s.
Clin Cancer Res. 2022 Oct 3;28(19):4173-4177. doi: 10.1158/1078-0432.CCR-22-0873.
Clin Cancer Res. 2022.
PMID: 35679021
Free PMC article.
Clinical Trial.